Bill
Bill > S1224
US S1224
US S1224Stop STALLING Act Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
summary
Introduced
04/29/2019
04/29/2019
In Committee
06/27/2019
06/27/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
A BILL To enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public heath concerns, and for other purposes. 1
AI Summary
This bill, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (or the Stop STALLING Act), empowers the Federal Trade Commission (FTC) to take enforcement action against "sham" citizen petitions. A sham petition is one that is objectively baseless and attempts to use the governmental process to interfere with a competitor's business, rather than raising legitimate public health concerns. The bill creates a presumption that a petition is part of a sham series of petitions if the Secretary of Health and Human Services has determined it was submitted primarily to delay approval of a competing generic drug or biosimilar and has referred that determination to the FTC. The bill authorizes the FTC to seek civil penalties against individuals or entities that submit or cause the submission of such sham petitions.
Committee Categories
Justice
Sponsors (2)
Last Action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 130. (on 06/28/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...